文献速递浆细胞疾病

泊马度胺、环磷酰胺和地塞米松治疗复发多发性骨髓瘤

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma.
PubMed 文献 · Blood · 2018-10-03

这项多中心2期试验评估每周口服泊马度胺-环磷酰胺-地塞米松(PCD)方案在来那度胺-硼替佐米-地塞米松(RVD)治疗后首次复发多发性骨髓瘤患者中的疗效与安全性。初始4周期后部分缓解及以上率为85%(82/97),A组48例中45例(94%)按计划接受自体干细胞移植,毒性以血液学为主且可控。

要点

  • RVD治疗后首次复发MM患者接受4周期PCD,部分缓解及以上率为85%(82/97)
  • A组48例中45例(94%)按计划完成自体干细胞移植
  • 毒性以血液学为主且可控

核心结论

  • PCD是RVD治疗后首次复发的有效治疗方案,4周期后部分缓解及以上率为85%,94%的计划自体干细胞移植得以实施,毒性以血液学为主且可控。

研究设计与样本

  • 多中心2期试验,评估每周口服PCD方案治疗来那度胺-硼替佐米-地塞米松(RVD)治疗后首次复发的多发性骨髓瘤患者。
  • 所有患者均接受RVD诱导和巩固治疗及1年来那度胺维持治疗(A组),其中一半患者在诱导后还接受了自体干细胞移植(B组)。
  • 复发时所有患者接受4个口服周期PCD:泊马度胺4 mg(第1-21天)、环磷酰胺300 mg(第1、8、15、22天)、地塞米松40 mg(28天周期第1-4天和第15-18天)。
  • A组有反应者接受自体干细胞移植并再接受2周期PCD,B组接受5周期PCD;所有患者接受泊马度胺-地塞米松维持治疗直至疾病进展。

主要发现

  • 初始4周期PCD后,97例可评估患者中82例(85%)获得缓解:完全缓解1例(1%)、非常好的部分缓解32例(33%)、部分缓解49例(51%)。
  • 3例(3%)疾病稳定,6例(6%)疾病进展(6例治疗失败)。
  • A组48例患者中45例(94%)按计划接受自体干细胞移植。

关键数值与推荐

  • 主要终点为初始4周期PCD后部分缓解或更好,实际达到82/97(85%)。
  • 缓解构成:完全缓解1例(1%)、非常好的部分缓解32例(33%)、部分缓解49例(51%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

It is important to have an effective therapy for patients with multiple myeloma (MM) at first relapse, particularly if an autologous stem cell transplant (ASCT) is considered at this stage. This multicenter, phase 2 trial evaluated the efficacy and safety of weekly oral pomalidomide-cyclophosphamide-dexamethasone (PCD) in patients with MM in first relapse after treatment with lenalidomide-bortezomib-dexamethasone (RVD). All patients had received RVD as induction and consolidation therapy, plus lenalidomide maintenance for 1 year (arm A). Half had also received an ASCT after induction (arm B). At MM relapse, all patients received 4 oral cycles of pomalidomide 4 mg (days 1-21), cyclophosphamide 300 mg (days 1, 8, 15, and 22), and dexamethasone 40 mg (days 1-4 and days 15-18 of a 28-day cycle; PCD). Responding patients in arm A underwent ASCT and received 2 additional cycles of PCD, whereas those in arm B received 5 cycles of PCD. All patients received pomalidomide-dexamethasone maintenance until disease progression. Primary end point was partial remission or better after the initial 4 cycles of PCD. Responses were obtained in 82/97 (85%) patients evaluated: complete remission (n = 1; 1%), very good partial remission (n = 32; 33%), and partial remission (n = 49; 51%). Three patients (3%) had stable disease, and 6 (6%) had disease progression (6 response failures). Forty-five (94%) of the 48 patients in arm A underwent planned ASCT. PCD was effective therapy after first relapse with RVD. After 4 cycles, the rate of partial remission or better was 85%, and 94% of planned ASCTs were performed. Toxicity was mostly hematologic and manageable. This trial was registered at www.clinicaltrials.gov as #NCT02244125.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Garderet L, Kuhnowski F, Berge B, et al. Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma. Blood. 2018. PMID: 30282798. doi:10.1182/blood-2018-07-863829

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。